This study aimed to investigate the utilisation of ATII in critically ill adults undergoing vasopressor therapy. The study included patients admitted to ICUs from January 1, 2018, to December 31, 2020, who received intravenous medications with vasopressor effects such as ATII, epinephrine, norepinephrine, phenylephrine, or vasopressin.

The primary outcome was the administration of ATII during the hospital stay.

Secondary outcomes included the quantity and duration of vasopressor use and the timing of ATII administration in relation to other vasopressors.

A total of 1,040,581 patients from 520 hospitals were included in the analysis. Of these, 2,019 patients were administered ATII.

ATII administration increased gradually from 0% of patients in January 2018 to 0.2% in December 2020.

The majority of hospitals did not use ATII.

17.1% of the hospitals that used ATII, the proportion of patients receiving it was relatively low.

Read More